SAM
TLX

Smartleaf Asset Management’s Telix Pharmaceuticals TLX Stock Holding History

Smartleaf Asset Management’s Portfolio TLX Stock Details TLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$332 Sell
37
-35
-49% -$267 ﹤0.01% 3283
2025
Q4 		$558 Buy
+72
New +$693 ﹤0.01% 3251

Other funds holding TLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
PIC
Portland Investment Counsel Burlington, Ontario, Canada $312M AUM 53.32% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
IWC
Integrated Wealth Concepts Waltham, Massachusetts $12.5B AUM 18.49% 1-Year Est. Return
RBI
Raiffeisen Bank International Vienna, Austria $8.53B AUM 46.94% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return

Smartleaf Asset Management's TLX Position: Q1 2026 in Review

Smartleaf Asset Management reduced its Telix Pharmaceuticals (TLX) stake by 49% in Q1 2026, selling an estimated $267 and leaving 37 shares worth $332. The position accounts for ﹤0.01% of the portfolio, ranked #3283.

Smartleaf Asset Management first reported a position in TLX in Q4 2025 and has held it in 2 quarters since. The position peaked at $558 in Q4 2025. 39 funds tracked by Wall St. Rank hold TLX as of Q1 2026.

  • Smartleaf Asset Management held 37 shares of Telix Pharmaceuticals worth $332 as of Q1 2026.
  • Smartleaf Asset Management sold 35 Telix Pharmaceuticals shares in Q1 2026, an estimated $267.
  • Telix Pharmaceuticals made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q1 2026, its #3283 holding.
  • Smartleaf Asset Management first reported a position in Telix Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Smartleaf Asset Management's Telix Pharmaceuticals position peaked at $558 in Q4 2025.
  • 39 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q1 2026.

Based on Smartleaf Asset Management's 13F filing for Q1 2026, filed 15 May 2026.